Brian Thomas Garibaldi

Brian Thomas Garibaldi

Auto-generated profile, based on publicly available information

Brian Thomas Garibaldi

Brian T. Garibaldi, MD, MEHP, is Director, Center for Bedside Medicine, and Charles Horace Mayo Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Ageing Research Reviews
Verified
Journal Article
Closed access
YCYiyin Chen
Yiyin Chen
SKSabra L. Klein
Sabra L. Klein
BGBrian T. Garibaldi
Brian T. Garibaldi
HLHuifen Li
Huifen Li
CWCunjin Wu
Cunjin Wu
SLSean Xiao Leng
Sean Xiao Leng

1 January 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
BGBrian T. Garibaldi
Brian T. Garibaldi
JFJacob Fiksel
Jacob Fiksel
JMJohn Muschelli
John Muschelli
MRMatthew L. Robinson
Matthew L. Robinson
MRMasoud Rouhizadeh
Masoud Rouhizadeh
AGAmita Gupta
Amita Gupta
This retrospective analysis from 5 Maryland and Washington, DC area hospitals determines factors on hospital admission predictive of severe disease or death from COVID-19 and describes patient traj... Visual Trajectories Among Patients Hospitalized for COVID-19 This retrospective analysis from 5 Maryland and Washington, DC, area hospitals determines factors on hospital admission predict... Background: Risk factors for progression of coronavirus 2019 (COVID-19) to severe disease or death are underexplored in U.S. cohorts. Objective: To determine the factors on hospital admission that ...

1 January 2013 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
BGBrian T. Garibaldi
Brian T. Garibaldi
FDFranco R. D’ALessio
Franco R. D’ALessio
JMJason R. Mock
Jason R. Mock
DFD. Clark Files
D. Clark Files
ECEric Chau
Eric Chau
LKLandon S. King
Landon S. King
Acute lung injury (ALI) causes significant morbidity and mortality. Fibroproliferation in ALI results in worse outcomes, but the mechanisms governing fibroproliferation remain poorly understood. Regulatory T cells (Tregs) are important in lung injury resolution. Their role in fibroproliferation is unknown. We sought to identify the role of Tregs in ALI fibroproliferation, using a murine model of lung injury. Wild-type (WT) and lymphocyte-deficient Rag-1−/− mice received intratracheal LPS. Fibroproliferation was characterized by histology and the measurement of lung collagen. Lung fibrocytes were measured by flow cytometry. To dissect the role of Tregs in fibroproliferation, Rag-1−/− mice received CD4+CD25+ (Tregs) or CD4+CD25− Tcells (non-Tregs) at the time of LPS injury. To define the role of the chemokine (C-X-C motif) ligand 12 (CXCL12)–CXCR4 pathway in ALI fibroproliferation, Rag-1−/− mice were treated with the CXCR4 antagonist AMD3100 to block fibrocyte recruitment. WT and Rag-1−/− mice demonstrated significant collagen deposition on Day 3 after LPS. WT mice exhibited the clearance of collagen, but Rag-1−/− mice developed persistent fibrosis. This fibrosis was mediated by the sustained epithelial expression of CXCL12 (or stromal cell-derived factor 1 [SDF-1]) that led to increased fibrocyte recruitment. The adoptive transfer of Tregs resolved fibroproliferation by decreasing CXCL12 expression and subsequent fibrocyte recruitment. Blockade of the CXCL12–CXCR4 axis with AMD3100 also decreased lung fibrocytes and fibroproliferation. These results indicate a central role for Tregs in the resolution of ALI fibroproliferation by reducing fibrocyte recruitment along the CXCL12–CXCR4 axis. A dissection of the role of Tregs in ALI fibroproliferation may inform the design of new therapeutic tools for patients with ALI.

21 May 2014 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
JMJ R Mock
J R Mock
BGB T Garibaldi
B T Garibaldi
NAN R Aggarwal
N R Aggarwal
JJJ Jenkins
J Jenkins
NLNathachit Limjunyawong
Nathachit Limjunyawong
FDF R D'ALessio
F R D'ALessio
Acute respiratory distress syndrome (ARDS) causes significant morbidity and mortality each year. There is a paucity of information regarding the mechanisms necessary for ARDS resolution. Foxp3+ regulatory T cells (Foxp3+ Treg cells) have been shown to be an important determinant of resolution in an experimental model of lung injury. We demonstrate that intratracheal delivery of endotoxin (lipopolysaccharide) elicits alveolar epithelial damage from which the epithelium undergoes proliferation and repair. Epithelial proliferation coincided with an increase in Foxp3+ Treg cells in the lung during the course of resolution. To dissect the role that Foxp3+ Treg cells exert on epithelial proliferation, we depleted Foxp3+ Treg cells, which led to decreased alveolar epithelial proliferation and delayed lung injury recovery. Furthermore, antibody-mediated blockade of CD103, an integrin, which binds to epithelial expressed E-cadherin decreased Foxp3+ Treg numbers and decreased rates of epithelial proliferation after injury. In a non-inflammatory model of regenerative alveologenesis, left lung pneumonectomy, we found that Foxp3+ Treg cells enhanced epithelial proliferation. Moreover, Foxp3+ Treg cells co-cultured with primary type II alveolar cells (AT2) directly increased AT2 cell proliferation in a CD103-dependent manner. These studies provide evidence of a new and integral role for Foxp3+ Treg cells in repair of the lung epithelium.

1 March 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
BGBrian T. Garibaldi
Brian T. Garibaldi
KWKunbo Wang
Kunbo Wang
MRMatthew L. Robinson
Matthew L. Robinson
SZScott L. Zeger
Scott L. Zeger
KBKaren Bandeen-Roche
Karen Bandeen-Roche
YXYanxun Xu
Yanxun Xu
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to progress, with more than 103 million global cases and more than 2.2 million deaths as of February 2, 2021.1 While the world awaits the distribution of effective vaccines, a number of pharmacologic agents have been studied for treatment of coronavirus disease 2019 (COVID-19), the syndrome caused by SARS-CoV-2. Remdesivir, a nucleotide analogue prodrug with in vitro effects against a broad array of RNA viruses,2-4 has received considerable attention.3,5,6 Clinical trials assessing the effectiveness of remdesivir have yielded conflicting results7-12; have not included a sufficient number of patients from groups most affected by COVID-19, such as Black or Latinx individuals13; and have not examined the coadministration of remdesivir with other drugs. The US Food and Drug Administration (FDA) approved the use of remdesivir for the treatment of hospitalized patients with COVID-1914 based mostly on the results of the Adaptive COVID-19 Treatment Trial (ACTT-1),11 whereas the World Health Organization (WHO) recommended against the use of remdesivir15 based on results from the Solidarity trial.12

21 December 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SKSara M Karaba
Sara M Karaba
GJGeorge Jones
George Jones
THTaylor Helsel
Taylor Helsel
LSL Leigh Smith
L Leigh Smith
RARobin Avery
Robin Avery
VFValeria Fabre
Valeria Fabre
Background: Bacterial infections may complicate viral pneumonias. Recent reports suggest that bacterial co-infection at time of presentation is uncommon in coronavirus disease 2019 (COVID-19); however, estimates were based on microbiology tests alone. We sought to develop and apply consensus definitions, incorporating clinical criteria to better understand the rate of co-infections and antibiotic use in COVID-19. Methods: A total of 1016 adult patients admitted to 5 hospitals in the Johns Hopkins Health System between March 1, 2020, and May 31, 2020, with COVID-19 were evaluated. Adjudication of co-infection using definitions developed by a multidisciplinary team for this study was performed. Both respiratory and common nonrespiratory co-infections were assessed. The definition of bacterial community-acquired pneumonia (bCAP) included proven (clinical, laboratory, and radiographic criteria plus microbiologic diagnosis), probable (clinical, laboratory, and radiographic criteria without microbiologic diagnosis), and possible (not all clinical, laboratory, and radiographic criteria met) categories. Clinical characteristics and antimicrobial use were assessed in the context of the consensus definitions. Results: Bacterial respiratory co-infections were infrequent (1.2%); 1 patient had proven bCAP, and 11 (1.1%) had probable bCAP. Two patients (0.2%) had viral respiratory co-infections. Although 69% of patients received antibiotics for pneumonia, the majority were stopped within 48 hours in patients with possible or no evidence of bCAP. The most common nonrespiratory infection was urinary tract infection (present in 3% of the cohort). Conclusions: Using multidisciplinary consensus definitions, proven or probable bCAP was uncommon in adults hospitalized due to COVID-19, as were other nonrespiratory bacterial infections. Empiric antibiotic use was high, highlighting the need to enhance antibiotic stewardship in the treatment of viral pneumonias.